CytoSorbents Reaches Cash-Flow Breakeven Before Restructuring Payments
Blood-purification company CytoSorbents reported on November 12, 2026 that revenue for the quarter ended September 30 rose 3% to $9.7 million, while it generated approximately $43,000 in positive operating cash flow excluding about $251,000 of restructuring-related payments. Total quarterly cash burn was approximately $200,000 including those payments. Cost Reductions Narrow the Loss Gross margin improved to 75% from 70% a year earlier, while operating expenses fell 11%. Net loss narrowed to…